New Test for Staph Infections
By Labmedica staff writers Posted on 30 Nov 2005 |
A new test has been launched that detects both methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible Staphylococcus aureus (MSSA).
The Staphaurex Plus is a rapid and convenient latex agglutination test that is able to detect MRSA as well as MSSA. The latex particles in Staphaurex Plus are coated with fibrinogen and specific polyclonal antibodies directed towards difficult Staph aureus strains, including MRSA. In the presence of target organisms, the latex particles agglutinate to provide a strong and easily visible positive reaction. In the absence of target organism, the particles remain in smooth suspension. The sensitivity of the test is
> 98% for all S aureus strains.
Everything required to perform the test is provided in the kit, including reaction cards, mixing sticks, and a control latex to eliminate nonspecific agglutination. Kits are available for 150 or 450 tests. The test was developed by Oxoid (Basingstoke, UK).
Oxoid has additional products available for the detection of MRSA. These include a latex agglutination test for the detection of penicillin-binding protein 2 expressed by the MecA gene for resistance in MRSA strains. The Staphytect Plus and Dryspot Staphytcct Plus latex agglutination tests are for the detection of MSSA and MRSA. Oxoid also offers products for screening samples for MRSA and for the detection of MRSA in routine swab samples.
Related Links:
Oxoid
The Staphaurex Plus is a rapid and convenient latex agglutination test that is able to detect MRSA as well as MSSA. The latex particles in Staphaurex Plus are coated with fibrinogen and specific polyclonal antibodies directed towards difficult Staph aureus strains, including MRSA. In the presence of target organisms, the latex particles agglutinate to provide a strong and easily visible positive reaction. In the absence of target organism, the particles remain in smooth suspension. The sensitivity of the test is
> 98% for all S aureus strains.
Everything required to perform the test is provided in the kit, including reaction cards, mixing sticks, and a control latex to eliminate nonspecific agglutination. Kits are available for 150 or 450 tests. The test was developed by Oxoid (Basingstoke, UK).
Oxoid has additional products available for the detection of MRSA. These include a latex agglutination test for the detection of penicillin-binding protein 2 expressed by the MecA gene for resistance in MRSA strains. The Staphytect Plus and Dryspot Staphytcct Plus latex agglutination tests are for the detection of MSSA and MRSA. Oxoid also offers products for screening samples for MRSA and for the detection of MRSA in routine swab samples.
Related Links:
Oxoid
Latest Industry News
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus
- AMP Publishes Best Practice Guidance for Slice Testing Approach in Diagnostics